Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04538742 · ClinicalTrials.gov registry record · Phase 1

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

A Phase 1 study of Metastatic Breast Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 1
Development phase
245
Enrollment target
20
Study locations

NCT04538742 is a Phase 1 study of Metastatic Breast Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 245 participants, above the 203-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (21% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04538742, a Phase 1 study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
245 participants
Enrollment target
20
Study locations

Study Summary

DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer

Conditions Studied

Metastatic Breast Cancer

Interventions

  • DRUG Paclitaxel
  • DRUG Trastuzumab deruxtecan
  • DRUG Tucatinib
  • DRUG Durvalumab
  • DRUG Pertuzumab

Study Locations (20)

Other

  • Research Site - Melbourne
  • Research Site - Barretos
  • Research Site - Belo Horizonte
  • Research Site - Natal
  • Research Site - Porto Alegre
  • Research Site - Porto Alegre
  • Research Site - Rio de Janeiro
  • Research Site - São Paulo
  • Research Site - São Paulo
  • Research Site - Sorocaba

New York

  • Research Site - Commack
  • Research Site - Harrison
  • Research Site - New York
  • Research Site - New York

Florida

  • Research Site - Fort Myers
  • Research Site - St. Petersburg

Ohio

  • Research Site - Columbus

Tennessee

  • Research Site - Nashville

Texas

  • Research Site - Fort Worth

Virginia

  • Research Site - Fairfax

Trial Details

FieldValue
Enrollment Target 245 participants
Start Date 2020-12-28
Est. Completion 2030-01-31
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04538742

The ClinicalTrials.gov registry entry for NCT04538742 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 203-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (21% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Paclitaxel is the first listed.

NCT04538742 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, New York, Florida.

Frequently Asked Questions

What is clinical trial NCT04538742 about?

NCT04538742 is a clinical study titled "A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer". DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer

What is the current status of trial NCT04538742?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 245 participants. The study started on 2020-12-28. Estimated completion is 2030-01-31.

What conditions does trial NCT04538742 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer.

What interventions are being tested in trial NCT04538742?

The interventions under investigation include: Paclitaxel (DRUG), Trastuzumab deruxtecan (DRUG), Tucatinib (DRUG), Durvalumab (DRUG), Pertuzumab (DRUG).

Who is sponsoring clinical trial NCT04538742?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04538742 being conducted?

This trial has 20 study locations across Florida, New York, Ohio, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Breast Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.